Introduction

Japan's Ministry of Health, Labour and Welfare (MHLW) has updated its import guidelines for health foods, requiring third-party testing reports for heavy metals and pesticide residues in Chinese herbal products starting April 1, 2026. This move directly impacts Chinese exporters of traditional medicine-based health supplements, particularly small and medium-sized enterprises (SMEs), and adds 10–12 days to the export process. The regulation affects key product categories like lingzhi spore powder, red ginseng capsules, and astragalus oral solutions.

Event Overview

On March 29, 2026, Japan's MHLW revised its Health Food Import Declaration Guidelines, mandating that all health products containing 'Kampo' or 'crude drug extracts' must submit full-item test reports from JIS Z 3101-accredited laboratories. The reports must cover lead, cadmium, mercury, arsenic, and five common organophosphorus pesticide residues. The policy takes effect on April 1, 2026.

Impacted Sub-Sectors

Direct Exporters

Chinese manufacturers and traders exporting herbal health products to Japan will face extended clearance times due to the additional testing requirements. SMEs lacking pre-existing testing partnerships may experience port delays.

Raw Material Suppliers

Upstream suppliers of herbal ingredients must now ensure compliance with Japan's stricter thresholds for contaminants, potentially requiring adjustments in sourcing or cultivation practices.

Testing Laboratories

JIS Z 3101-certified labs in China and Japan are likely to see increased demand, but capacity bottlenecks could emerge during peak export periods.

Key Action Points for Industry

Prioritize Testing Partnerships

Secure agreements with accredited labs to avoid last-minute scheduling conflicts. Larger exporters may consider in-house JIS certification.

Review High-Risk Ingredients

Focus on products with historically higher heavy metal or pesticide residue risks, such as soil-cultivated herbs.

Adjust Supply Chain Timelines

Factor in the 10–12 day testing buffer for production and shipping schedules, especially for time-sensitive orders.

Industry Perspective

From an industry standpoint, this regulation reflects Japan's growing emphasis on imported supplement safety rather than a targeted trade barrier. However, the immediate operational disruption for Chinese exporters is significant. Observers note this could accelerate consolidation among smaller producers unable to absorb the compliance costs.

Conclusion

While the policy aligns with global trends in health product safety, its abrupt implementation poses logistical challenges for China's herbal export sector. Companies should treat this as a baseline requirement rather than a one-time compliance hurdle, as similar regulations may expand to other markets.

Source

Japan Ministry of Health, Labour and Welfare: Revised Health Food Import Declaration Guidelines (March 29, 2026). Ongoing monitoring recommended for potential updates to the list of regulated substances or testing protocols.